January 13, 2024
1 min read
Save
Smith & Nephew completes acquisition of CartiHeal, knee regeneration technology
Key takeaways:
- Smith & Nephew has completed acquisition of CartiHeal and its Agili-C knee regeneration technology.
- The acquisition closed at $180 million, with an additional $150 million contingent on financial performance.
Smith & Nephew has announced the completed acquisition of CartiHeal for $180 million, with an additional $150 million contingent on future financial performance, according to a press release.
Smith & Nephew will acquire CartiHeal’s Agili-C implant technology, a knee cartilage regeneration treatment for patients with osteochondral lesions.
“With its proven superiority to current standard of care, Agili-C has the potential to transform cartilage repair outcomes,” Scott Schaffner, president of sports medicine at Smith & Nephew, said in the release. “Our expertise in regenerative therapy and leadership in knee repair gives me great confidence that this will be a significant value creator for Smith & Nephew,” he added.
Published by:
Read more about